Phaseline

Companies › Wuhan Humanwell Innovative Drug Research and Development Center Limited Company

Wuhan Humanwell Innovative Drug Research and Development Center Limited Company: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Oncology, Immunology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HW071021–Phase 1Advanced Solid TumorsFeb 2027
HWS116 Injection–Phase 1Advanced Solid TumorsAug 2027
HW201877–Phase 1Healthy Participants–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07373457HW201877Phase 1Healthy ParticipantsImmunologyMar 2026
NCT06882135HW071021Phase 1Advanced Solid TumorsOncologyFeb 2027
NCT07413328HWS116 InjectionPhase 1Advanced Solid TumorsOncologyAug 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.